Illumina bets on Pacific, not nanopores
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Congenica aims to turn data into information
Sequencing data is all well and good, but what does it mean?
Oxford Nanopore, the disruptive unicorn gunning for Illumina
Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders?
Smaller medtechs soar in ’17 but could now be too expensive
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.